Literature DB >> 26653080

A prospective study on the causes of notably raised alanine aminotransferase (ALT).

Helgi Kristinn Björnsson1, Sigurdur Olafsson2, Ottar M Bergmann2, Einar S Björnsson1,2.   

Abstract

OBJECTIVE: High levels of alanine aminotransferase (ALT) can be a marker of severe liver disease with variable aetiologies and prognosis. Very few prospective studies have been undertaken on the aetiology and prognosis of patients with high ALT levels. No population-based prospective study has systematically evaluated drug-induced liver injury (DILI) among these patients. The objective was to determine the aetiology and prognosis of patients with high ALT.
MATERIALS AND METHODS: In a catchment area of 160,000 inhabitants, a population-based prospective study identified all adult patients with serum level of ALT >500 U/L during a 12-month period. All underwent thorough diagnostic work-up and follow-up. In suspected DILI, causality was assessed with Roussel Uclaf Causality Assessment Method.
RESULTS: A total of 155 patients were identified with ALT >500 U/L, 12 children and one with ALT of non-liver-related origin, leaving 142 patients for the analysis: 73 (51%) males, median age 52 (IQR 36-68, range 19-89 years). The most common causes were choledocholithiasis 48/142 (34%), ischaemic hepatitis 26 (18%), viral hepatitis 16 (11%) and DILI 15 (11%), hepatobiliary malignancy (n = 6), surgery/interventions (n = 8) and other aetiologies (n = 23). No specific aetiology was found in 6% of cases. In the total study cohort 99 (70%) required hospitalisation, 78 (55%) had jaundice and 22 (16%) died, liver-related death in 10%, 35% in IH and 7% in DILI.
CONCLUSIONS: The most common cause of notably high ALT was choledocholithiasis. Ischaemic hepatitis was a common aetiology with approximately 35% liver-related mortality. Viral hepatitis and DILI were important aetiologies among these patients.

Entities:  

Keywords:  Aetiology; alanine aminotransferase; liver disease; outcome

Mesh:

Substances:

Year:  2015        PMID: 26653080     DOI: 10.3109/00365521.2015.1121516

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

Review 1.  Biomarkers of drug-induced liver injury.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Adv Pharmacol       Date:  2019-03-06

2.  Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.

Authors:  Marina Curra; Amanda F Gabriel; Maria Beatriz C Ferreira; Marco Antonio T Martins; André T Brunetto; Lauro J Gregianin; Manoela Domingues Martins
Journal:  Support Care Cancer       Date:  2021-04-12       Impact factor: 3.603

3.  Lowering the upper limit of serum alanine aminotransferase levels may reveal significant liver disease in the elderly.

Authors:  Hemda Schmilovitz-Weiss; Rachel Gingold-Belfer; Alon Grossman; Nidal Issa; Doron Boltin; Yichayaou Beloosesky; Nira Morag Koren; Joseph Meyerovitch; Avraham Weiss
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

Review 4.  Clinical management of patients with drug-induced liver injury (DILI).

Authors:  Einar S Björnsson
Journal:  United European Gastroenterol J       Date:  2021-06-28       Impact factor: 6.866

5.  Correlations between mitochondrial DNA haplogroup D5 and chronic hepatitis B virus infection in Yunnan, China.

Authors:  Xiao Li; Tai-Cheng Zhou; Chang-Hui Wu; Li-Lin Tao; Rui Bi; Li-Jun Chen; De-Yao Deng; Chang Liu; Newton O Otecko; Yang Tang; Xin Lai; Liang Zhang; Jia Wei
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

6.  Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort.

Authors:  Danny Con; Andrew Buckle; Amanda J Nicoll; John S Lubel
Journal:  JGH Open       Date:  2019-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.